1. |
|
|
2. |
- Maierbeck, P., et al.
(författare)
-
Probing the single particle structure around Ca-54 with one-neutron knock-out
- 2008
-
Ingår i: AIP Conference Proceedings. - 1551-7616 .- 0094-243X. ; 1012, s. 89-93
-
Konferensbidrag (refereegranskat)abstract
- The nuclei Ca-47 and Ti-55 were populated in one-neutron knock-out reactions at relativistic energies. Momentum distributions of the residual nuclei as well as gamma-ray spectra were measured at the GSI fragment separator (FRS). Preliminary results of the ongoing analysis including cross sections and spin/parity assignments are presented.
|
|
3. |
- Maierbeck, P., et al.
(författare)
-
Structure of 55Ti from relativistic one-neutron knockout
- 2009
-
Ingår i: Physics Letters B. - : Elsevier BV. - 0370-2693. ; 675:1, s. 22-27
-
Tidskriftsartikel (refereegranskat)abstract
- Results are presented from a one-neutron knockout reaction at relativistic energies on 56Ti using the GSI FRS as a two-stage magnetic spectrometer and the Miniball array for gamma-ray detection. Inclusive and exclusive longitudinal momentum distributions and cross-sections were measured enabling the determination of the orbital angular momentum of the populated states. First-time observation of the 955(6) keV -hole state in 55Ti is reported. The measured data for the first time proves that the ground state of 55Ti is a 1/2- state, in agreement with shell-model calculations using the GXPF1A interaction that predict a sizable N=34 gap in 54Ca.
|
|
4. |
|
|
5. |
- Vanrenterghem, Y, et al.
(författare)
-
Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized controlled trial
- 2005
-
Ingår i: American Journal of Transplantation. - : Elsevier BV. - 1600-6135. ; 5:1, s. 87-95
-
Tidskriftsartikel (refereegranskat)abstract
- Modern immunosuppressive regimens reduce the acute rejection rate by combining a cornerstone immunosuppressant like tacrolimus or cyclosporine with adjunctive agents like corticosteroids, mycophenolate mofetil (MMF) or azathioprine, often associated with untoward side effects. A 6-month randomized study was conducted in 47 European centers. Triple therapy with tacrolimus (trough levels 5-15 ng/mL), corticosteroids (dosage 10 mg/day) and MMF (1 g/day) was administered for 3 months. From day 92, patients either continued with triple therapy (control, n = 277), or stopped steroids (n = 279), or stopped MMF (n = 277). Surrogate markers for long-term benefits were changes in lipid profiles and occurrence of hematological, gastrointestinal and infectious complications. The 6-month acute rejection incidence (biopsy-proven) was similar in all groups (17.0% vs. 15.1% vs. 14.8%, p = 0.744), although the incidence after month 3 was higher in the steroid stop group than in the two other groups. Mean reductions in total cholesterol (18.9 mg/dL [0.49 mmol/L]) and LDL-cholesterol (8.1 mg/dL [0.21 mmol/L]) between months 4 and 6 were greater in the steroid stop group (p < 0.001). Leukopenia (p = 0.0082), serious CMV infection (p = 0.024), anemia (p = NS) and diarrhea (p = NS) were less frequent in the MMF stop group. In a study population of immunologically low-risk patients' withdrawal of corticosteroids or MMF from a tacrolimus-based therapy at 3 months was feasible. A longer follow-up will be needed to confirm the expected advantages for the long-term outcome and to assess the long-term safety of this minimization of immunosuppressive therapy.
|
|